Medications are recognized as an increasingly common cause for uveitis [
1]. In this article, we report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Progress in pharmacological research has led to the development of novel, more effective, and more specific drugs for melanoma. Some of them could be responsible for side effects, such as uveitis. The mitogen-activated protein kinase (MAPK) pathway plays a key role in the development of melanoma. Mutations in effectors of this pathway, such as BRAF and MEK, lead to increased survival and proliferation of melanoma cells [
2]. Targeting these molecules has led to the development of promising drugs. Vemurafenib and Dabrafenib are BRAF
V600 inhibitors licensed for the treatment of adults presenting the BRAF
V600E mutation and nonresectable or metastatic melanoma [
2]. Trametinib is a MEK inhibitor approved for the same indication, as well as for a combination with Dabrafenib [
2]. A combination of these molecules has shown an improved response rate in patients with metastatic melanoma [
2]. A recent publication by Guedj et al. [
3] described a series of seven patients who developed Vemurafenib-induced bilateral non-granulomatous anterior uveitis. Vemurafenib-induced uveitis was also reported by Choe et al. [
4]. Another article describes a severe bilateral vitritis and optic disk leakage occurring 3 weeks after starting combined treatment with Dabrafenib and Trametinib, with resolution 6 weeks after the cessation of both drugs [
5]. The large multicentre trials for the approval of Dabrafenib report the occurrence of 1 % of uveitis of unspecified severity [
6]. The occurrence of serous retinal detachments (SRDs), once associated with moderate anterior uveitis, has been reported in Trametinib therapy [
7,
8]. Uveitis was resolved on topical therapy without the cessation of Trametinib.